TransCode Therapeutics announced publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology. The abstract, published in the June 1 supplemental issue of the journal, was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology, ASCO. The study shows that inhibition of microRNA-10b, the therapeutic target of TTX-MC138, in breast cancer cells impaired the capacity of cancer stem cells to create new tumors and become metastatic. TransCode believes that these findings are important because cancer stem cells have long been known to play a critical role in cancer initiation, metastasis, recurrence, and resistance to therapy. TTX-MC138 is designed to inhibit the oncogenic RNA, microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors, including breast cancer. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers. In a preclinical model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals. This study comes on the heels of preclinical studies in human breast cancer in animals demonstrating complete regressions of metastatic disease. In addition to murine models of cancer, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RNAZ:
- TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
- TransCode Therapeutics Announces Closing of $7 Million Public Offering
- TransCode Therapeutics Announces Pricing of $7 Million Public Offering
- TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
- TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue